EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus

Hugo J van Dooren, Mieke van Schaik iD, Annemarie L Dorjée, Eline J Arends, Meggan Mackay, Laura Cooney, David A Fox, David Wofsy, Dawn Smilek iD, Cynthia Aranow iD, Maria Dall'Era, Tom W J Huizinga und 5 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Hugo J van Dooren und 16 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Antinuclear, B-Lymphocytes, Rituximab. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Leiden University Medical Center, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The presence of antinuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti–double‐stranded DNA (anti‐dsDNA) is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA serum levels are associated with disease activity. Antibody dynamics of other ANAs, such as antibodies targeting RNA‐binding proteins (RBPs), are often considered more stable compared to anti‐dsDNA. However, anti‐RBPs may be heterogeneous in nature, and their fluctuation has not been extensively analyzed. Therefore, we aimed to study the dynamics of the different ANAs and their susceptibility to B cell–targeting treatments in patients with SLE.

Methods

Seroconversion of specific ANAs was analyzed using electronic health records from patients with SLE. Titers of specific ANAs and anti‐varicella zoster virus (VZV) were determined in serum samples from a longitudinal cohort of patients with SLE and serum from patients with SLE treated with rituximab and belimumab.

Results

Anti‐Smith (anti‐Sm) and anti‐RNP, similar to anti‐dsDNA titers, seroconverted more frequently compared to anti–SS‐A/SS‐B. Furthermore, anti‐Sm/RNP and anti‐dsDNA titers, but not anti–SS‐A/SS‐B titers, fluctuated significantly compared to stable anti‐VZV controls. Likewise, reductions in anti‐dsDNA and anti‐Sm/RNP titers after B cell–depleting treatment were comparable in magnitude. However, only anti‐dsDNA titer reductions associated with clinical outcomes.

Conclusion

Together, these results show that anti‐Sm/RNP and anti‐dsDNA, in contrast to anti–SS‐A/SS‐B, frequently fluctuate and their levels can decrease following B cell–targeted treatments. Thus, distinct ANAs have variable kinetics, potentially reflecting their derivation from different B cell differentiation pathways. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, AntinuclearB-LymphocytesRituximabAntibodies, Monoclonal, HumanizedHumansFemaleMaleAdultMiddle AgedLongitudinal StudiesImmunosuppressive Agents

Substanzen

Antibodies, AntinuclearRituximabbelimumabAntibodies, Monoclonal, HumanizedImmunosuppressive Agents

Autor:innen und Institutionen

  • Leiden University Medical Center, Leiden, The Netherlands.
  • Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, New York.
  • University of Michigan, Ann Arbor, and University of California, San Francisco.
  • University of California, San Francisco.

ORCID-Profile: Mieke van Schaik, Dawn Smilek, Cynthia Aranow, Betty Diamond, Jolien Suurmond

Förderung

  • NIAID NIH HHS
  • Leiden University Medical Center
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

van Dooren, H. J., van Schaik, M., Dorjée, A. L., Arends, E. J., Mackay, M., Cooney, L., Fox, D. A., Wofsy, D., Smilek, D., Aranow, C., Dall'Era, M., Huizinga, T. W. J., van Kooten, C., Toes, R. E. M., Diamond, B., Teng, Y. K. O., & Suurmond, J. (2025). Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. https://doi.org/10.1002/art.43219

Vancouver

van Dooren HJ, van Schaik M, Dorjée AL, Arends EJ, Mackay M, Cooney L, et al. Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2025. doi:10.1002/art.43219

BibTeX
@article{vanDooren2025,
  author = {van Dooren, Hugo J and van Schaik, Mieke and Dorjée, Annemarie L and Arends, Eline J and Mackay, Meggan and Cooney, Laura and Fox, David A and Wofsy, David and Smilek, Dawn and Aranow, Cynthia and Dall'Era, Maria and Huizinga, Tom W J and van Kooten, Cees and Toes, René E M and Diamond, Betty and Teng, Y K Onno and Suurmond, Jolien},
  title = {Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43219}
}
Kostenlos starten →